Patents Examined by Parithosh K. Tungaturthi
-
Patent number: 7524930Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.Type: GrantFiled: October 5, 2006Date of Patent: April 28, 2009Assignee: Green Peptide Co., LtdInventor: Kyogo Itoh
-
Patent number: 7432354Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.Type: GrantFiled: October 5, 2006Date of Patent: October 7, 2008Assignee: Green Peptide Co., Ltd.Inventor: Kyogo Itoh
-
Patent number: 7427660Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.Type: GrantFiled: October 5, 2006Date of Patent: September 23, 2008Assignee: Green Peptide Co., Ltd.Inventor: Kyogo Itoh
-
Patent number: 7413736Abstract: A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idiotype also can be used as an immunogenic vaccine.Type: GrantFiled: July 25, 2007Date of Patent: August 19, 2008Assignee: Immunomedics, Inc.Inventors: Shui-on Leung, Michele J. Losman, Hans Hansen
-
Patent number: 7408037Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.Type: GrantFiled: October 5, 2006Date of Patent: August 5, 2008Assignee: Green Peptide Co., Ltd.Inventor: Kyogo Itoh
-
Patent number: 7404270Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.Type: GrantFiled: October 5, 2006Date of Patent: July 29, 2008Assignee: Green Peptide Co., Ltd.Inventor: Kyogo Itoh
-
Patent number: 7399469Abstract: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.Type: GrantFiled: March 25, 2005Date of Patent: July 15, 2008Assignee: PDL BioPharma, Inc.Inventors: Yongke Zhang, Vanitha Ramakrishnan, Debbie Law
-
Patent number: 7396917Abstract: Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.Type: GrantFiled: December 2, 2002Date of Patent: July 8, 2008Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Shana Frederickson, Mark Renshaw
-
Patent number: 7396911Abstract: This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof.Type: GrantFiled: July 7, 2003Date of Patent: July 8, 2008Assignee: Genetics Institute, LLCInventors: Stephen H. Herrmann, Stephen L. Swanberg
-
Patent number: 7390635Abstract: The present invention provides recombinant peptides that specifically and selectively bind to the human milk fat globule (HMFG) antigen, BA46. In particular, the present invention provides recombinant variants of the Mc3 antibody, including humanized versions of Mc3. The variant Mc3 peptides are particularly useful for diagnostic, prognostic, and therapeutic applications in the field of breast cancer. The present invention also provides methods for the humanization of antibodies such as murine monoclonal antibodies. The novel humanization methods are applied to the production of humanized Mc3 antibodies and it is shown that these humanized antibodies retain the ability to engage in high affinity binding to their cognate antigen. Such humanization enables the use of these antibodies for immunodiagnostic and immunotherapeutic applications in humans.Type: GrantFiled: October 13, 2004Date of Patent: June 24, 2008Assignee: Cancer Research Institute of Contra CostaInventors: Fernando J. R. Do Couto, Robert L. Ceriani, Jerry A. Peterson
-
Patent number: 7375193Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.Type: GrantFiled: September 29, 2006Date of Patent: May 20, 2008Assignee: Genentech, Inc.Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-Yee Chen
-
Patent number: 7365166Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.Type: GrantFiled: September 28, 2006Date of Patent: April 29, 2008Assignee: Genentech, Inc.Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-Yee Chen
-
Patent number: 7358355Abstract: Disclosed are an antibody against human para-thyroid-hormone-related protein, a DNA coding for the antibody, a recombinant vector containing the DNA, a transformant transformed with the recombinant vector, a method for preparation of the antibody, and uses of the antibody.Type: GrantFiled: February 2, 2005Date of Patent: April 15, 2008Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Koh Sato, Yuji Wakahara, Naohiro Yabuta
-
Patent number: 7355011Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.Type: GrantFiled: May 2, 2003Date of Patent: April 8, 2008Assignee: UCB Pharma S.A.Inventors: Andrew George Popplewell, Simon Peter Tickle, Heather Margaret Ladyman
-
Patent number: 7355012Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.Type: GrantFiled: September 25, 2002Date of Patent: April 8, 2008Assignee: United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Ira H. Pastan, Giuliana Salvatore, Richard Beers, Robert J. Kreitman
-
Patent number: 7351811Abstract: A gene that is a modulator of tumor growth and metastasis in certain cancer types is provided. SCC-112 (about 150 kDa) and/or a mutant form of SCC-112 (about 65 kDa) is a tumor suppressor molecule. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of SCC-112 such as breast and kidney cancers.Type: GrantFiled: October 6, 2003Date of Patent: April 1, 2008Assignee: Georgetown UniversityInventors: Usha Kasid, Deepak Kumar, Imran Ahmad
-
Patent number: 7348419Abstract: A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idiotype also can be used as an immunogenic vaccine.Type: GrantFiled: March 25, 2004Date of Patent: March 25, 2008Assignee: Immunomedics, Inc.Inventors: Shui-on Leung, Michele J. Losman, Hans Hansen
-
Patent number: 7332580Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.Type: GrantFiled: April 4, 2003Date of Patent: February 19, 2008Assignees: The Regents of the University of California, Fox Chase Cancer CenterInventors: Gregory P. Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
-
Patent number: 7312318Abstract: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.Type: GrantFiled: March 3, 2003Date of Patent: December 25, 2007Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Shui-on Leung, Zhengxing Qu, David M. Goldenberg
-
Patent number: 7300655Abstract: The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.Type: GrantFiled: August 1, 2003Date of Patent: November 27, 2007Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg